Boston Scientific Trading Volume Drops 29.35% Ranked 87th in Daily Volume

On April 24, 2025, Boston Scientific (BSX) saw a trading volume of $907 million, marking a 29.35% decrease from the previous day. The stock ranked 87th in terms of trading volume for the day. Boston Scientific's shares rose by 2.24%, marking the third consecutive day of gains, with a total increase of 8.08% over the past three days.

Boston Scientific reported its first-quarter 2025 results, highlighting significant growth across various segments. The MedSurg segment reported revenues of $1.58 billion, up 11.7% year over year on a reported basis and 5.3% organically. Within this segment, the Endoscopy unit generated $673 million in revenues, up 5.5% organically, while Urology revenues were $633 million, reflecting organic growth of 4.4%. The Neuromodulation business reported $271 million in revenues, highlighting a 6.8% rise organically year over year.

The Cardiovascular segment, which generates the majority of the company's revenues, reported $3.09 billion in the first quarter, up 26.2% year over year on a reported basis and 25.6% organically. The Cardiology business sales totaled $2.43 billion, up 31.2% year over year organically, while the Peripheral Interventions unit generated $656 million in sales, up 7.4%.

Boston Scientific's first-quarter earnings per share (EPS) were $0.75, surpassing the estimated $0.67. The company's revenue for the quarter totaled $4.66 billion, up 20.9% year over year on a reported basis and 22.2% on an operational basis. Organic growth, adjusted for foreign currency fluctuations and certain recent acquisitions and divestments, was 18.2%.

For the full year 2025, Boston Scientific anticipates net sales to grow approximately 15-17% on a reported basis and nearly 12-14% on an organic basis. The company also expects full-year adjusted EPS in the range of $2.87-$2.94. For the second quarter of 2025, revenue growth is projected in the range of approximately 17.5-19.5% on a reported basis and 13-15% organically. Adjusted earnings are expected in the range of 71-73 cents per share.